Open AccessPrognostic Significance of Low HER2 Expression in Patients With Early Hormone Receptor Positive Breast Cancer
Author(s) -
GEORGE DOUGANIOTIS,
LOUKAS KONTOVINIS,
EFROSINI MARKOPOULOU,
ALEXANDRA AINALI,
THOMAS ZARAMPOUKAS,
IOANNIS NATSIOPOULOS,
Konstantinos Papazisis
Publication year - 2022
Publication title -
cancer diagnosis and prognosis
Language(s) - English
Resource type - Journals
ISSN - 2732-7787
DOI - 10.21873/cdp.10111
Subject(s) - breast cancer , medicine , immunohistochemistry , oncology , hormonal therapy , trastuzumab , hormone receptor , cancer , progesterone receptor , population , hormone therapy , lobular carcinoma , pathology , ductal carcinoma , estrogen receptor , environmental health
A possible role of antibody-drug conjugates against tumors with low HER2-expression, leads to the emergence of a new "low-HER2" classification in breast cancer, encompassing tumors from the hormonal-receptor-positive and the triple-negative subgroups. There is a need for data (clinical trial data and real-world evidence) that will accurately describe this population, the risk of recurrence and the possible benefit of HER2 targeted therapies.